AKINTUNDE BELLO, PhD
Chair, IQ Clinical Pharmacology Leadership Group (CPLG) (2015-2018)
IQ CPLG member (2012-present)
Vice President Clinical Pharmacology and Pharmacokinetics, Bristol-Myers Squibb
PhD, Inhalation Pharmaceutics, Drug Metabolism, Pharmacokinetics, King's College London
WHAT FACTORS SHAPED THE GROWTH OF IQ?
IQ's "special sauce" is the commitment and engagement of the member companies, specifically their representatives' dedication to the mission and goals fo IQ, improving how drugs and therapies are developed which serves the needs of the patients.
WHAT DOES THE NEXT 10 YEARS LOOK LIKE FOR IQ?
IQ initatives will reflect the new medicines and therapeutic modalities that are coming to the fore such as cell therapies, regenerative medicine, novel delivery technologies (such as micro robotic drug products). The role of precision medicine will continue to expand as will the use of machine learning and AI approaches across all of our disciplines.
WHAT IQ ACCOMPLISHMENTS STAND OUT MOST FROM THE LAST 10 YEARS?
WHAT IS ONE OF YOUR FONDEST MEMORIES OF YOUR INVOLVEMENT IN IQ?
The collaborative spirit of the member companies and representatives in supporting the many CPLG working group initiatives. I am particularly proud of the work the IQ did and my role in the organization of an FDA/Brooking Institution/IQ Open meeting on the role of Clinical Pharmacology in drug development.